Mark H Wilcox

List of Publications by Year
in descending order

205	17,948	28736 57	17891 125
papers	citations	h-index	g-index

211	211	211	12282
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Omadacycline and Clostridioides difficile: A Systematic Review of Preclinical and Clinical Evidence. Annals of Pharmacotherapy, 2023, 57, 184-192.	0.9	8
2	From the hospital toilet to the ward: A pilot study on microbe dispersal to multiple hospital surfaces following hand drying using a jet air dryer versus paper towels. Infection Control and Hospital Epidemiology, 2022, 43, 241-244.	1.0	5
3	Can SARS-CoV-2 be transmitted via faeces?. Current Opinion in Gastroenterology, 2022, 38, 26-29.	1.0	14
4	Modeling fomiteâ€mediated SARSâ€CoVâ€2 exposure through personal protective equipment doffing in a hospital environment. Indoor Air, 2022, 32, .	2.0	10
5	The potential of microbiome replacement therapies for Clostridium difficile infection. Current Opinion in Gastroenterology, 2022, 38, 1-6.	1.0	10
6	Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials. Infectious Diseases and Therapy, 2022, 11, 217-230.	1.8	4
7	An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones. Journal of Antimicrobial Chemotherapy, 2022, 77, 1155-1165.	1.3	16
8	A global perspective on improving patient care in uncomplicated urinary tract infection: expert consensus and practical guidance. Journal of Global Antimicrobial Resistance, 2022, 28, 18-29.	0.9	18
9	Comparison of Whole-Genome Sequence-Based Methods and PCR Ribotyping for Subtyping of Clostridioides difficile. Journal of Clinical Microbiology, 2022, 60, JCM0173721.	1.8	22
10	A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018. Eurosurveillance, 2022, 27, .	3.9	14
11	Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes. Clinical Infectious Diseases, 2021, 73, e2616-e2624.	2.9	7
12	Swab-yourself Trial With Economic Monitoring and Testing for Infections Collectively (SYSTEMATIC): Part 1. A Diagnostic Accuracy and Cost-effectiveness Study Comparing Clinician-taken vs Self-taken Rectal and Pharyngeal Samples for the Diagnosis of Gonorrhea and Chlamydia. Clinical Infectious Diseases, 2021, 73, e3172-e3180.	2.9	10
13	Perturbations of the gut microbiome in anti-CCP positive individuals at risk of developing rheumatoid arthritis. Rheumatology, 2021, 60, 3380-3387.	0.9	16
14	Is there a causal relationship between trehalose consumption and Clostridioides difficile infection?. Current Opinion in Gastroenterology, 2021, 37, 9-14.	1.0	1
15	Eravacycline, a novel tetracycline derivative, does not induceClostridioides difficileinfection in anin vitrohuman gut model. Journal of Antimicrobial Chemotherapy, 2021, 76, 171-178.	1.3	7
16	Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection. Npj Biofilms and Microbiomes, 2021, 7, 16.	2.9	43
17	Global Landscape of Clostridioides Difficile Phylogeography, Antibiotic Susceptibility, and Toxin Polymorphisms by Post-Hoc Whole-Genome Sequencing from the MODIFY I/II Studies. Infectious Diseases and Therapy, 2021, 10, 853-870.	1.8	17
18	Protecting the Microbiota. Journal of Infectious Diseases, 2021, 223, S290-S295.	1.9	4

#	Article	IF	Citations
19	Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clinical Infectious Diseases, 2021, 73, e1029-e1044.	2.9	270
20	Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study. BMJ, The, 2021, 374, n1637.	3.0	66
21	Trehalose-Induced Remodelling of the Human Microbiota Affects Clostridioides difficile Infection Outcome in an In Vitro Colonic Model: A Pilot Study. Frontiers in Cellular and Infection Microbiology, 2021, 11, 670935.	1.8	18
22	Healthcare-associated COVID-19 in England: A national data linkage study. Journal of Infection, 2021, 83, 565-572.	1.7	42
23	Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clinical Infectious Diseases, 2021, 73, 755-757.	2.9	105
24	The use of first-generation cephalosporin antibiotics, cefalexin and cefradine, is not associated with induction of simulated Clostridioides difficile infection. Journal of Antimicrobial Chemotherapy, 2021, 77, 148-154.	1.3	7
25	Development and clinical validation of an automated cell cytotoxicity neutralization assay for detecting Clostridioides difficile toxins in clinically relevant stools samples. Anaerobe, 2021, 71, 102415.	1.0	3
26	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2021, 76, iv2-iv8.	1.3	11
27	A Phase 3 Randomized Controlled Trial (MICROCARE) to Evaluate the Efficacy of DAV132 in Preventing Clostridioides Difficile Infection in Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome and Treated with Intensive Chemotherapy. Blood, 2021, 138, 4437-4437.	0.6	0
28	Method comparison for the direct enumeration of bacterial species using a chemostat model of the human colon. BMC Microbiology, 2020, 20, 2.	1.3	5
29	A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent Clostridioides difficile Infection in Pre-clinical Models. Frontiers in Microbiology, 2020, 11, 578903.	1.5	13
30	Optimization of an Assay To Determine Colonization Resistance to Clostridioides difficile in Fecal Samples from Healthy Subjects and Those Treated with Antibiotics. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	4
31	Modifiable healthcare factors affecting 28-day survival in bloodstream infection: a prospective cohort study. BMC Infectious Diseases, 2020, 20, 545.	1.3	13
32	In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. Journal of Antimicrobial Chemotherapy, 2020, 75, 2879-2884.	1.3	7
33	Metabolite Identification of Helicobacter Pylori Supernatant Using Near-IR Raman Spectroscopy. , 2020, , .		0
34	Recontamination of Healthcare Surfaces by Repeated Wiping with Biocide-Loaded Wipes: â€œOne Wipe, One Surface, One Direction, Disposeâ€•as Best Practice in the Clinical Environment. International Journal of Molecular Sciences, 2020, 21, 9659.	1.8	5
35	The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridiumdifficile Infection: Current Understanding and Gap Analysis. Open Forum Infectious Diseases, 2020, 7, ofaa114.	0.4	31
36	Metagenomics reveals impact of geography and acute diarrheal disease on the Central Indian human gut microbiome. Gut Microbes, 2020, 12, 1752605.	4.3	22

#	Article	IF	Citations
37	In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	14
38	Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment. MSphere, 2020, 5, .	1.3	13
39	Investigation of the effect of the adsorbent DAV131A on the propensity of moxifloxacin to induce simulated Clostridioides (Clostridium) difficile infection (CDI) in an in vitro human gut model. Journal of Antimicrobial Chemotherapy, 2020, 75, 1458-1465.	1.3	2
40	Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 1014-1018.	1.3	5
41	Caution is warranted in using cephamycin antibiotics against recurrent Clostridioides difficile infection. Nature Microbiology, 2020, 5, 236-236.	5.9	7
42	Ultrasensitive Clostridioides difficile Toxin Testing for Higher Diagnostic Accuracy. Journal of Clinical Microbiology, 2020, 58, .	1.8	6
43	Clostridium difficile: Investigating Transmission Patterns Between Infected and Colonized Patients Using Whole Genome Sequencing. Clinical Infectious Diseases, 2019, 68, 204-209.	2.9	55
44	Lower Urinary Tract Infections: Management, Outcomes and Risk Factors for Antibiotic Re-prescription in Primary Care. EClinicalMedicine, 2019, 14, 23-31.	3.2	28
45	Emerging drugs for treating methicillin-resistantStaphylococcus aureus. Expert Opinion on Emerging Drugs, 2019, 24, 191-204.	1.0	9
46	Combating resistance while maintaining innovation: the future of antimicrobial stewardship. Future Microbiology, 2019, 14, 1331-1341.	1.0	16
47	Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infectious Diseases, The, 2019, 19, 265-274.	4.6	41
48	Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials. International Journal of Antimicrobial Agents, 2019, 53, 830-837.	1.1	5
49	The perils of PCR-based diagnosis of Clostridioides difficile infections: Painful lessons from clinical trials. Anaerobe, 2019, 60, 102048.	1.0	7
50	Valuing antibiotics: The role of the hospital clinician. International Journal of Antimicrobial Agents, 2019, 54, 16-22.	1.1	1
51	Service evaluation of alcohol-release door plates: an addition to hand hygiene. Journal of Hospital Infection, 2019, 103, e97-e100.	1.4	0
52	Cross-sectional study of the prevalence, causes and management of hospital-onset diarrhoea. Journal of Hospital Infection, 2019, 103, 200-209.	1.4	10
53	â€˜The method used to dry washed hands affects the number and type of transient and residential bacteria remaining on the skinâ€™. Journal of Hospital Infection, 2019, 102, 473-474.	1.4	0
54	Dissemination of multiple carbapenem resistance genes in an in vitro gut model simulating the human colon. Journal of Antimicrobial Chemotherapy, 2019, 74, 1876-1883.	1.3	21

#	Article	IF	Citations
55	Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	24
56	A Review of Mixed Strain Clostridium difficile Colonization and Infection. Frontiers in Microbiology, 2019, 10, 692.	1.5	12
57	A Role for Tetracycline Selection in Recent Evolution of Agriculture-Associated Clostridium difficile PCR Ribotype 078. MBio, 2019, 10, .	1.8	46
58	Ultrasensitive Detection of Clostridium difficile Toxins Reveals Suboptimal Accuracy of Toxin Gene Cycle Thresholds for Toxin Predictions. Journal of Clinical Microbiology, 2019, 57, .	1.8	10
59	Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study. Open Forum Infectious Diseases, 2019, 6, ofz436.	0.4	1
60	Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe. Diagnostic Microbiology and Infectious Disease, 2019, 93, 154-158.	0.8	11
61	Effect of fluoroquinolone resistance mutation Thr-82â†'Ile on Clostridioides difficile fitness. Journal of Antimicrobial Chemotherapy, 2019, 74, 877-884.	1.3	11
62	Omadacycline Gut Microbiome Exposure Does Not Induce Clostridium difficile Proliferation or Toxin Production in a Model That Simulates the Proximal, Medial, and Distal Human Colon. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	31
63	Factors affecting removal of bacterial pathogens from healthcare surfaces during dynamic wiping. Textile Reseach Journal, 2019, 89, 580-589.	1.1	4
64	Impact of Clostridium difficile toxin gene PCR result on decisions to de-isolate patients: Do the ends justify the means?. Journal of Infection Prevention, 2018, 19, 138-140.	0.5	4
65	Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases, 2018, 66, e1-e48.	2.9	1,695
66	European Practice for CDI Treatment. Advances in Experimental Medicine and Biology, 2018, 1050, 117-135.	0.8	9
67	A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1. Clinical Infectious Diseases, 2018, 66, 1222-1229.	2.9	41
68	Reply to Joseph etÂal.. Journal of Hospital Infection, 2018, 99, 434-435.	1.4	0
69	Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases, 2018, 66, 987-994.	2.9	900
70	Understanding Clostridium difficile Colonization. Clinical Microbiology Reviews, 2018, 31, .	5.7	206
71	The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011â€"2014. Clinical Microbiology and Infection, 2018, 24, 724-731.	2.8	96
72	Gastrointestinal infections. Current Opinion in Gastroenterology, 2018, 34, 1-2.	1.0	0

#	Article	IF	Citations
73	Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. International Journal of Antimicrobial Agents, 2018, 52, 233-240.	1.1	15
74	Subtyping of Clostridium difficile PCR ribotypes 591, 106 and 002, the dominant strain types circulating in Medellin, Colombia. PLoS ONE, 2018, 13, e0195694.	1.1	10
75	Correlation between restriction endonuclease analysis and PCR ribotyping for the identification of Clostridioides (Clostridium) difficile clinical strains. Anaerobe, 2018, 54, 1-7.	1.0	9
76	Real-Life Evidence for Tedizolid Phosphate in the Treatment of Cellulitis and Wound Infections: A Case Series. Infectious Diseases and Therapy, 2018, 7, 387-399.	1.8	6
77	Environmental contamination by bacteria in hospital washrooms according to hand-drying method: a multi-centre study. Journal of Hospital Infection, 2018, 100, 469-475.	1.4	28
78	Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1035-1044.	4.6	65
79	Sensitivity of Single-Molecule Array Assays for Detection of Clostridium difficile Toxins in Comparison to Conventional Laboratory Testing Algorithms. Journal of Clinical Microbiology, 2018, 56, .	1.8	19
80	Bezlotoxumab for Prevention of RecurrentClostridium difficileInfection. New England Journal of Medicine, 2017, 376, 305-317.	13.9	675
81	Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infectious Diseases, The, 2017, 17, 411-421.	4.6	269
82	Is AGREE II a counsel of perfection? A letter commenting on Lytvyn et al. Infection Control and Hospital Epidemiology, 2017, 38, 636-638.	1.0	0
83	Bezlotoxumab and Recurrent Clostridium difficile Infection. New England Journal of Medicine, 2017, 376, 1593-1596.	13.9	13
84	Evaluation of the novel artus C. difficile QS-RGQ, VanR QS-RGQ and MRSA/SA QS-RGQ assays for the laboratory diagnosis of Clostridium difficile infection (CDI), and for vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) screening. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 823-829.	1.3	3
85	Clostridium difficile in England: can we stop washing our hands? â€“ Authors' reply. Lancet Infectious Diseases, The, 2017, 17, 478-479.	4.6	1
86	Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infectious Diseases, The, 2017, 17, 735-744.	4.6	91
87	Contribution to Clostridium Difficile Transmission of Symptomatic Patients With Toxigenic Strains Who Are Fecal Toxin Negative. Clinical Infectious Diseases, 2017, 64, 1163-1170.	2.9	45
88	Role of surface energy and nano-roughness in the removal efficiency of bacterial contamination by nonwoven wipes from frequently touched surfaces. Science and Technology of Advanced Materials, 2017, 18, 197-209.	2.8	19
89	In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	10
90	Epidemiology of Escherichia coli bacteraemia in England: results of an enhanced sentinel surveillance programme. Journal of Hospital Infection, 2017, 95, 365-375.	1.4	92

#	Article	IF	Citations
91	The potential of alcohol release doorplates to reduce surface contamination during hand contact. Journal of Hospital Infection, 2017, 97, 424-429.	1.4	4
92	Pilot study to determine whether microbial contamination levels in hospital washrooms are associated with hand-drying method. Journal of Hospital Infection, 2017, 97, 201-203.	1.4	3
93	Is there a relationship between the presence of the binary toxin genes in Clostridium difficile strains and the severity of C. difficile infection (CDI)?. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 2405-2415.	1.3	27
94	The start of another infection prevention learning curve: reducing healthcare-associated Gram-negative bloodstream infections. Journal of Hospital Infection, 2017, 97, 205-206.	1.4	12
95	Role of cephalosporins in the era ofClostridium difficileinfection. Journal of Antimicrobial Chemotherapy, 2017, 72, 1-18.	1.3	60
96	Preservation of Gut Microbiome Following Ridinilazole vs. Fidaxomicin Treatment of Clostridium difficile Infection. Open Forum Infectious Diseases, 2017, 4, S526-S527.	0.4	4
97	Comparison of Control of Clostridium difficile Infection in Six English Hospitals Using Whole-Genome Sequencing. Clinical Infectious Diseases, 2017, 65, 433-441.	2.9	40
98	Epidemiology of Clostridium difficile in infants in Oxfordshire, UK: Risk factors for colonization and carriage, and genetic overlap with regional C. difficile infection strains. PLoS ONE, 2017, 12, e0182307.	1.1	82
99	Molecular, microbiological and clinical characterization of Clostridium difficile isolates from tertiary care hospitals in Colombia. PLoS ONE, 2017, 12, e0184689.	1.1	15
100	Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia. Journal of Infection, 2016, 73, 45-53.	1.7	60
101	An In Vitro Model of the Human Colon: Studies of Intestinal Biofilms and Clostridium difficile Infection. Methods in Molecular Biology, 2016, 1476, 223-234.	0.4	11
102	European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clinical Microbiology and Infection, 2016, 22, S63-S81.	2.8	424
103	Molecular characterisation of Czech Clostridium difficile isolates collected in 2013â€“2015. International Journal of Medical Microbiology, 2016, 306, 479-485.	1.5	26
104	OC-043â€...Mutation of the Ferric Uptake Regulator (FUR) Severely Impairs Toxin Production in a Human in vitro Gut Model of Clostridium Difficile Infection. Gut, 2016, 65, A25.2-A26.	6.1	1
105	A MLST Clade 2 Clostridium difficile strain with a variant TcdB induces severe inflammatory and oxidative response associated with mucosal disruption. Anaerobe, 2016, 40, 76-84.	1.0	16
106	Antibiotic strategies in the era of multidrug resistance. Critical Care, 2016, 20, 136.	2.5	202
107	Ridinilazole: a novel therapy for Clostridium difficile infection. International Journal of Antimicrobial Agents, 2016, 48, 137-143.	1.1	41
108	Efficacy of vancomycin extended-dosing regimens for treatment of simulatedClostridium difficileinfection within anin vitrohuman gut model. Journal of Antimicrobial Chemotherapy, 2016, 71, 986-991.	1.3	14

#	Article	IF	Citations
109	Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators. Antimicrobial Agents and Chemotherapy, 2016, 60, 689-692.	1.4	25
110	Potential of lactoferrin to prevent antibiotic-inducedClostridium difficileinfection. Journal of Antimicrobial Chemotherapy, 2016, 71, 975-985.	1.3	20
111	Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 206-216.	8.2	294
112	Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection. Antibiotics, 2015, 4, 267-298.	1.5	56
113	DAV132, an Adsorbent-Based Product, Protects the Gut Microbiome and Prevents Clostridium difficile Infections During Moxifloxacin Treatments. Open Forum Infectious Diseases, 2015, 2, .	0.4	4
114	SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. Journal of Antimicrobial Chemotherapy, 2015, 70, 182-189.	1.3	35
115	Efficacy of alternative fidaxomicin dosing regimens for treatment of simulatedClostridium difficileinfection in anin vitrohuman gut model. Journal of Antimicrobial Chemotherapy, 2015, 70, 2598-2607.	1.3	26
116	Preface. Infectious Disease Clinics of North America, 2015, 29, xiii-xiv.	1.9	2
117	Diagnostic Pitfalls in Clostridium difficile Infection. Infectious Disease Clinics of North America, 2015, 29, 63-82.	1.9	44
118	Lack of Evidence for an Unmet Need to Treat Clostridium difficile Infection in Infants Aged <2 Years: Expert Recommendations on How to Address This Issue. Clinical Infectious Diseases, 2015, 60, 912-918.	2.9	24
119	Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis. Vaccine Journal, 2015, 22, 1033-1039.	3.2	12
120	In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. Journal of Antimicrobial Chemotherapy, 2015, 70, 1751-1756.	1.3	32
121	Comparison of the Vidas C. difficile GDH Automated Enzyme-Linked Fluorescence Immunoassay (ELFA) with Another Commercial Enzyme Immunoassay (EIA) (Quik Chek-60), Two Selective Media, and a PCR Assay for gluD for Detection of Clostridium difficile in Fecal Samples. Journal of Clinical Microbiology, 2015, 53, 1931-1934.	1.8	16
122	A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections. BMC Infectious Diseases, 2015, 15, 91.	1.3	36
123	Mycobacterial DNA Extraction for Whole-Genome Sequencing from Early Positive Liquid (MGIT) Cultures. Journal of Clinical Microbiology, 2015, 53, 1137-1143.	1.8	90
124	Recurrence of dual-strainClostridium difficileinfection in anin vitrohuman gut model. Journal of Antimicrobial Chemotherapy, 2015, 70, 2316-2321.	1.3	7
125	The Control of Methicillin-Resistant Staphylococcus aureus Blood Stream Infections in England. Open Forum Infectious Diseases, 2015, 2, ofv035.	0.4	67
126	Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clinical Microbiology and Infection, 2015, 21, 248.e9-248.e16.	2.8	218

#	Article	IF	Citations
127	Development and Validation of an Internationally-Standardized, High-Resolution Capillary Gel-Based Electrophoresis PCR-Ribotyping Protocol for Clostridium difficile. PLoS ONE, 2015, 10, e0118150.	1.1	176
128	Surveillance of antibiotic susceptibility of Enterobacteriaceae isolated from urine samples collected from community patients in a large metropolitan area, 2010â€“2012. Epidemiology and Infection, 2014, 142, 399-403.	1.0	16
129	International Clostridium difficile animal strain collection and large diversity of animal associated strains. BMC Microbiology, 2014, 14, 173.	1.3	105
130	Editorial Commentary: The Trials and Tribulations of Treating Clostridium difficile Infection--One Step Backward, One Step Forward, but Still Progress. Clinical Infectious Diseases, 2014, 59, 355-357.	2.9	10
131	Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model. Journal of Antimicrobial Chemotherapy, 2014, 69, 2137-2147.	1.3	42
132	Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infectious Diseases, The, 2014, 14, 1208-1219.	4.6	308
133	Microbiological comparison of hand-drying methods: the potential for contamination of the environment, user, and bystander. Journal of Hospital Infection, 2014, 88, 199-206.	1.4	35
134	Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. Journal of Antimicrobial Chemotherapy, 2014, 69, 2426-2433.	1.3	25
135	Clostridium difficile ribotype 126 in southern Taiwan: A cluster of three symptomatic cases. Anaerobe, 2014, 30, 188-192.	1.0	24
136	Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. Journal of Antimicrobial Chemotherapy, 2014, 69, 451-462.	1.3	47
137	In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. Journal of Antimicrobial Chemotherapy, 2014, 69, 697-705.	1.3	58
138	Development and Validation of a Chemostat Gut Model To Study Both Planktonic and Biofilm Modes of Growth of Clostridium difficile and Human Microbiota. PLoS ONE, 2014, 9, e88396.	1.1	54
139	Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infectious Diseases, The, 2013, 13, 936-945.	4.6	405
140	Diverse Sources of C. difficile Infection Identified on Whole-Genome Sequencing. New England Journal of Medicine, 2013, 369, 1195-1205.	13.9	595
141	Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nature Genetics, 2013, 45, 109-113.	9.4	669
142	Interventions to improve antibiotic prescribing practices for hospital inpatients. , 2013, , CD003543.		823
143	Comparison of Multilocus Variable-Number Tandem-Repeat Analysis and Whole-Genome Sequencing for Investigation of Clostridium difficile Transmission. Journal of Clinical Microbiology, 2013, 51, 4141-4149.	1.8	69
144	Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery. Journal of Antimicrobial Chemotherapy, 2013, 68, 2078-2082.	1.3	26

#	Article	IF	Citations
145	Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. Journal of Antimicrobial Chemotherapy, 2013, 68, 1305-1311.	1.3	35
146	Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. Journal of Antimicrobial Chemotherapy, 2013, 68, 168-176.	1.3	98
147	Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model. Journal of Antimicrobial Chemotherapy, 2013, 68, 1842-1849.	1.3	16
148	Mixed infection by Clostridium difficile in an in vitro model of the human gut. Journal of Antimicrobial Chemotherapy, 2013, 68, 1139-1143.	1.3	14
149	Parameters for the Mathematical Modelling of Clostridium difficile Acquisition and Transmission: A Systematic Review. PLoS ONE, 2013, 8, e84224.	1.1	13
150	Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model. Journal of Antimicrobial Chemotherapy, 2012, 67, 951-954.	1.3	26
151	Policy development for Clostridium difficile. Journal of Antimicrobial Chemotherapy, 2012, 67, i19-i22.	1.3	5
152	Progress with a difficult infection. Lancet Infectious Diseases, The, 2012, 12, 256-257.	4.6	7
153	Changing Epidemiology of Clostridium difficile Infection Following the Introduction of a National Ribotyping-Based Surveillance Scheme in England. Clinical Infectious Diseases, 2012, 55, 1056-1063.	2.9	204
154	Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. Journal of Hospital Infection, 2012, 81, 1-14.	1.4	262
155	Clostridium difficile infection in Europe: a hospital-based survey. Lancet, The, 2011, 377, 63-73.	6.3	924
156	Clinical Clostridium difficile: Clonality and Pathogenicity Locus Diversity. PLoS ONE, 2011, 6, e19993.	1.1	150
157	Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. Journal of Antimicrobial Chemotherapy, 2011, 66, 1537-1546.	1.3	28
158	Fluoroquinolones in the treatment of severe community-acquired. British Journal of Hospital Medicine (London, England: 2005), 2011, Suppl, S1-7.	0.2	0
159	The Changing Epidemiology of Clostridium difficile Infections. Clinical Microbiology Reviews, 2010, 23, 529-549.	5.7	748
160	Point-Counterpoint: What Is the Current Role of Algorithmic Approaches for Diagnosis of Clostridium difficile Infection?. Journal of Clinical Microbiology, 2010, 48, 4347-4353.	1.8	97
161	CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy, 2010, 65, iv41-iv51.	1.3	111
162	CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy, 2010, 65, iv53-iv65.	1.3	126

#	Article	IF	Citations
163	Relatedness of Human and Animal Clostridium difficile PCR Ribotype 078 Isolates Determined on the Basis of Multilocus Variable-Number Tandem-Repeat Analysis and Tetracycline Resistance. Journal of Clinical Microbiology, 2010, 48, 3744-3749.	1.8	101
164	Multilocus Sequence Typing of Clostridium difficile. Journal of Clinical Microbiology, 2010, 48, 770-778.	1.8	399
165	Mecillinam: a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model. Journal of Antimicrobial Chemotherapy, 2009, 63, 838-839.	1.3	13
166	Recent initiatives to reduce the spread of meticillin-resistant Staphylococcus aureus. British Journal of Hospital Medicine (London, England: 2005), 2009, 70, 399-401.	0.2	1
167	Tolevamer Is Not Efficacious in the Neutralization of Cytotoxin in a Human Gut Model of Clostridium difficile Infection. Antimicrobial Agents and Chemotherapy, 2009, 53, 2202-2204.	1.4	39
168	Complicated Skin and Skinâ€Structure Infections and Catheterâ€Related Bloodstream Infections: Noninferiority of Linezolid in a Phase 3 Study. Clinical Infectious Diseases, 2009, 48, 203-212.	2.9	260
169	Effects of Exposure of Clostridium difficile PCR Ribotypes 027 and 001 to Fluoroquinolones in a Human Gut Model. Antimicrobial Agents and Chemotherapy, 2009, 53, 412-420.	1.4	48
170	Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. Journal of Antimicrobial Chemotherapy, 2009, 63, 520-525.	1.3	71
171	Comparison of Nine Commercially Available Clostridium difficile Toxin Detection Assays, a Real-Time PCR Assay for C . difficile tcdB , and a Glutamate Dehydrogenase Detection Assay to Cytotoxin Testing and Cytotoxigenic Culture Methods. Journal of Clinical Microbiology, 2009, 47, 3211-3217.	1.8	302
172	Future gazing in the management of multiply drug-resistant Gram-positive infection. Journal of Infection, 2009, 59, S75-S80.	1.7	8
173	European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clinical Microbiology and Infection, 2009, 15, 1053-1066.	2.8	353
174	The tide of antimicrobial resistance and selection. International Journal of Antimicrobial Agents, 2009, 34, S6-S10.	1.1	41
175	Reply to Holtschlag. Infection Control and Hospital Epidemiology, 2008, 29, 191-192.	1.0	1
176	A case-control study of community-associated Clostridium difficile infection. Journal of Antimicrobial Chemotherapy, 2008, 62, 388-396.	1.3	327
177	Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. Journal of Antimicrobial Chemotherapy, 2008, 62, 1078-1085.	1.3	55
178	Emergence of reduced susceptibility to metronidazole in Clostridium difficile. Journal of Antimicrobial Chemotherapy, 2008, 62, 1046-1052.	1.3	230
179	Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. Journal of Antimicrobial Chemotherapy, 2007, 60, 83-91.	1.3	87
180	Systematic Review of Antimicrobial Drug Prescribing in Hospitals. Emerging Infectious Diseases, 2006, 12, 211-216.	2.0	119

#	Article	IF	Citations
181	Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. Journal of Antimicrobial Chemotherapy, 2006, 58, 1062-1065.	1.3	70
182	Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. Journal of Antimicrobial Chemotherapy, 2005, 56, 717-725.	1.3	128
183	Molecular Epidemiology of Endemic Clostridium difficile Infection and the Significance of Subtypes of the United Kingdom Epidemic Strain (PCR Ribotype 1). Journal of Clinical Microbiology, 2005, 43, 2685-2696.	1.8	39
184	Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. Journal of Antimicrobial Chemotherapy, 2005, 55, 974-982.	1.3	90
185	Antibiotic prescribing as a risk factor for MRSA. British Journal of Hospital Medicine (London,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	0.2	9
186	Update on linezolid: the first oxazolidinone antibiotic. Expert Opinion on Pharmacotherapy, 2005, 6, 2315-2326.	0.9	69
187	Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. Journal of Antimicrobial Chemotherapy, 2004, 53, 335-344.	1.3	101
188	Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. Journal of Antimicrobial Chemotherapy, 2004, 53, 882-884.	1.3	177
189	Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. Journal of Antimicrobial Chemotherapy, 2004, 54, 168-172.	1.3	89
190	Health-care-associated infection: morbidity, mortality and costs. British Journal of Hospital Medicine, 2004, 65, 88-91.	0.3	14
191	Clostridium difficile infection and pseudomembranous colitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 475-493.	1.0	80
192	Efficacy of linezolid versus comparator therapies in Gram-positive infections. Journal of Antimicrobial Chemotherapy, 2003, 51, 27ii-35.	1.3	28
193	Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. Journal of Antimicrobial Chemotherapy, 2003, 52, 96-102.	1.3	84
194	Laboratory diagnosis of Clostridium perfringens antibiotic-associated diarrhoea. Journal of Medical Microbiology, 2002, 51, 891-894.	0.7	60
195	Reduced susceptibility ofClostridium difficileto metronidazole. Journal of Antimicrobial Chemotherapy, 2001, 48, 741-742.	1.3	77
196	In situ measurement of linezolid and vancomycin concentrations in intravascular catheter-associated biofilm. Journal of Antimicrobial Chemotherapy, 2001, 47, 171-175.	1.3	34
197	Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates. Journal of Antimicrobial Chemotherapy, 2001, 47, 244-246.	1.3	18
198	A five year outbreak of methicillin-susceptible Staphylococcus aureus phage type 53,85 in a regional neonatal unit. Epidemiology and Infection, 2000, 124, 37-45.	1.0	29

#	Article	IF	Citations
199	Respiratory antibiotic use and Clostridium difficile infection: is it the drugs or is it the doctors?. Thorax, 2000, 55, 633-634.	2.7	16
200	In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. Journal of Antimicrobial Chemotherapy, 2000, 46, 551-556.	1.3	48
201	Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Alimentary Pharmacology and Therapeutics, 1998, 12, 1217-1223.	1.9	104
202	Clostridium difficile--setting the scene. Journal of Antimicrobial Chemotherapy, 1998, 41, 1-3.	1.3	12
203	Treatment of Clostridium difficile infection. Journal of Antimicrobial Chemotherapy, 1998, 41, 41-46.	1.3	93
204	Clostridium difficile infection: appendix. Journal of Antimicrobial Chemotherapy, 1998, 41, 71-72.	1.3	42
205	Clostridium difficile. , 0, , 557-566.		0